In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis

Juan M Arriaga1,2, Kacey Ronaldson-Bouchard3, Florencia Picech4

  • 1Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 10032, USA. juan.arriaga@mssm.edu.

Oncogene
|March 7, 2024
PubMed

Insights

Researchers identified CITED2 as a key driver of prostate cancer bone metastasis. This discovery offers new molecular targets for preventing and treating this deadly cancer spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis Research

Background:

  • Metastatic prostate cancer frequently spreads to bone, leading to significant mortality.
  • Limited understanding of molecular drivers hinders effective treatment strategies for bone metastasis.
  • Previous studies identified molecular alterations in prostate cancer metastasis, but their role in bone tropism remains unclear.

Purpose of the Study:

  • To identify novel molecular drivers and suppressors of prostate cancer bone metastasis.
  • To elucidate the functional relevance of molecular alterations in prostate cancer bone tropism.
  • To uncover new therapeutic targets for managing bone metastatic prostate cancer.

Main Methods:

  • Genome-wide CRISPR activation and inhibition screens were employed to identify key genes.
  • Functional validation studies were conducted to confirm identified targets.
  • An innovative organ-on-a-chip invasion platform was utilized to study bone tropism.

Main Results:

  • Multiple genetic drivers and suppressors of prostate cancer metastasis were identified through CRISPR screens.
  • The transcriptional modulator CITED2 was confirmed as a novel driver of prostate cancer bone metastasis.
  • The study uncovered several new potential molecular targets for treating bone metastatic disease.

Conclusions:

  • CITED2 plays a critical role in promoting prostate cancer metastasis to bone.
  • This research provides novel insights into the molecular mechanisms of bone metastasis.
  • The identified targets offer promising avenues for developing future therapeutic interventions for prostate cancer bone metastasis.

Related Concept Videos

Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
4.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.9K